Appointments at Cetero, Harlan, Numerate and Idea Pharma – People on the move

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Cetero, Harlan, Numerate and Idea Pharma.

James “Jay” Dixon has been named senior vice president (SVP), quality and compliance at Cetero Research. Dixon has more than 25 years of biopharm experience working at companies including MedImmune and Covance.

Harlan Laboratories has hired Manuela Leone to succeed Kuno Sommer as president of contract research services. Leone has worked at Pharmacia, Fidia, MDS Pharma Services, Galderma and Icon Clinical Research during her 18 years in the industry.

David Jobes has joined Numerate as SVP of business and corporate development. Before the appointment Jobes ran his own consultancy. He has also worked at Presbio, VaxGen, Applied Biosystems and the US National Institutes of Health (NIH).

Outcomes Health Information Solutions has recruited Michael Mickens as SVP of life sciences. Mickens joins from Sentrx and has also worked at etrials, Galt Associates and QED solutions.

Also, Outcomes Health has appointed Chris Conte as SVP of sales and marketing. Conte has more than 15 years of experience from working at companies including TriZetto, Misys Healthcare Systems and Oracle.

Matt Smith has been named as VP of business operations at Clinovo. Smith has 20 years of industry experience from working at Clinimetrics, where he was CEO, and Quintiles.

Phase II specialists Idea Pharma has appointed Pankaj Oza to its IDEAtion delivery team. Oza has previously worked at Norgine International and Bristol-Myers Squibb.

Jos Schneiders is to retire as president of DSM Netherlands for personal reasons in July 2011. Schneiders has worked at DSM for almost 35 years and will continue on a part-time basis for a year after his retirement.

During this year Schneiders will transition responsibilities to Atzo Nicolaï. Nicolaï is a member of the Dutch House of Representatives and held ministerial positions for five years in the 2000s.